Collaboration Agreements - Additional Information (Details)			1 Months Ended			3 Months Ended		6 Months Ended
	Aug. 17, 2021 USD ($)	Jul. 01, 2021 USD ($)	Jan. 31, 2022 USD ($)	Jan. 31, 2018 USD ($)	Oct. 31, 2017 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue						$ 465,400,000		$ 465,400,000		$ 307,900
Research and development expense						54,534,000	$ 47,818,000	$ 107,577,000	$ 93,551,000
GlaxoSmithKline plc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Effective date of agreement	Aug. 17, 2021
Upfront payments		$ 700,000,000
Upfront payment received	$ 500,000,000		$ 200,000,000
Percentage of development cost								0.60
Collaboration revenue						21,300,000	0	$ 42,400,000	0
Research and development expense						3,300,000		8,800,000
GlaxoSmithKline plc | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval						1,500,000,000		$ 1,500,000,000
Alector
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of development cost								0.40
AbbVie Biotechnology Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments					$ 205,000,000
Upfront payment received				$ 200,000,000	5,000,000
Exclusive option rights exercised for each program					250,000,000
Collaboration revenue						58,600,000	$ 6,600,000	$ 61,900,000	$ 10,700,000
Deferred revenue						$ 55,500,000		55,500,000		$ 117,400,000
AbbVie Biotechnology Limited | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval					$ 242,800,000
Innovent
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue								0
Development milestone								11,500,000
Sales milestone								$ 112,500,000